-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Most CD7-positive malignant tumors belong to highly aggressive lymphomas or leukemias with rapid disease progression and poor prognosis
Lymphoma Leukemia FDA
On April 19, 2022, the first subject of the Phase I clinical trial of PA3-17 injection developed by Boshengji Pharmaceutical Technology (Suzhou) Co.
Phase I clinical study of PA3-17 injection in the treatment of adult patients with relapsed/refractory CD7-positive hematolymphatic malignancies Boshengji Pharma’s CD7-targeted CAR-T cell injection was granted orphan drug designation by the U.
The trial is the world's first autologous CAR-T registration clinical trial based on the CD7 target.
CAR-T
About PA3-17 Injection
About PA3-17 Injection About PA3-17 InjectionDifferent from traditional CD19-CAR-T and BCMA-CAR-T, the development and clinical application of CD7-CAR-T cells face huge challenges, including: tumor T cells and normal T cells co-express CD7.
Infect
Boshengji has been developing CD7 single-domain antibodies since 2012, and has successively developed CD7 immunotoxin and CD7-CAR-NK, and finally successfully developed the world's first autologous CD7-CAR with First-in-class potential -T cells
immunity
About Boshengji
About BoshengjiAbout BoshengjiIt is the vision of Boshengji to become a leader in the research and development of innovative cell drugs.
The autologous CD7-CAR-T cell injection independently developed by the company is of great clinical value for the treatment of refractory and relapsed T-cell and NK-cell malignancies
manage
In the first half of 2021, Boshengji completed the A round of financing led by Yuansheng Venture Capital, Puen Guoxin Equity Investment and Xiantong Capital; in January 2022, it completed the investment jointly led by CICC Qide and Huatai Zijin , Panyi Capital and Huatong Capital jointly invested in the B round of financing
leave a message here
